IRVINE, Calif., May 11, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO) today announced that the United States District Court for the Northern District of California has issued a schedule for a summary judgment briefing and trial date in response to a joint stipulation, which was filed by both SenoRx and Hologic on April 14, 2009 in their pending matter before the Court. The joint stipulation requested that the Court allow summary judgment briefing and argument as to certain patent validity and infringement issues.
The schedule set by the Court is set forth below.
For summary judgment:
Opening briefs: May 20, 2009
Opposition briefs: June 19, 2009
Reply briefs: July 10, 2009
Argument: August 21, 2009
Trial Start Date: October 13
Based on the above court schedule, SenoRx reaffirms its estimate that patent litigation expense in the second quarter of 2009 remains unchanged from a range between $450,000 and $600,000. SenoRx will provide additional guidance on litigation expense when results for the second quarter of 2009 are reported.
About SenoRx
SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 1,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.
The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605